Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology & Drugs -- Ignore unavailable to you. Want to Upgrade?

To: SusieQ1065 who wrote (103)	7/9/2002 3:00:53 AM
From: 2MAR$	Read Replies (1) \| Respond to of 232

Biotech dates I could find : ABGX=8/23...ests= -41c ADRX=8/26...ests=9c AFFX=8/24...ests=1c AMGN=8/24....ests=34c BGEN=8/18....ests=31c CEPH=9/5....ests=21c CHIR=8/24 ...est= 27c CELG=8/25? ...est=.0.0 GILD=8/30...ests=3c GENZ=8/17...est=26c ICOS=8/25...ests=-54c IDPH=8/17...est=19c IMCL=9/15...ests= -41c IMNX=?? MEDI=8/25...ests= -12c MLNM=8/16....ests= -19c MYGN=9/6...ests = -18 more ....but looks like MLNM, GENZ and IDPH are up to the plate tues/weds next week , and BGEN following following thursday.

To: SusieQ1065 who wrote (103)	7/9/2002 5:11:31 PM
From: 2MAR$	Respond to of 232

LGND Ligand Pharms sees Q2 revs lower; warns for full year (9.54 - $7.00) Company says Q2 product sales were negatively affected "by approximately $6-8 million" at quarter-end by several major wholesalers' decisions not to purchase as well as by lower-than-expected demand; sees full year revs between $82 and $90 million with different product mix vs the current consensus estimate for revs of $128 mln; expects worldwide sales of its existing products, excluding AVINZA, to range between $50-$55 million, with no change to the full-year guidance including AVINZA.

To: SusieQ1065 who wrote (103)	7/9/2002 8:16:21 PM
From: 2MAR$	Respond to of 232

Shares of drugmaker NOVN ($20-$14.90) skid on Wyeth hormone-study news stockcharts.com[h,a]daclyiay[pc20!c200!f][vc60][iut!Lh5,5!La12,26,9]&pref=G CHICAGO (AP) -- Shares of Noven Pharmaceuticals Inc. (NasdaqNM:NOVN - News) dropped sharply Tuesday after government researchers halted a study of Wyeth Pharmaceuticals' hormone replacement therapy, citing concerns about risks of breast cancer and heart disease. ADVERTISEMENT Noven, a Miami-based developer of drug-delivery systems, also sells hormone replacement therapies for women. "People are just taking down anything associated with women's health," said Michael Hearle, an analyst with Leerink Swann & Co. He said Noven's combination hormone replacement product represents "a very small percentage" of the company's revenue. Wyeth, whose shares suffered a steep drop, said a study on combination hormone replacement therapy, or HRT, from the Women's Health Initiative Study found that combination HRT increased the risk of cardiovascular disease, and, over time, increased the risk of breast cancer. The National Institutes of Health is discontinuing the combination HRT arm of the study due to the increased risk of invasive breast cancer and a determination of an overall lack of long-term benefit. Wyeth paid for the follow-up study, which was published last week in the Journal of the American Medical Association, or JAMA. A spokesperson for Noven wasn't immediately available for comment.